55 2 Macrophage Metabolic Reprogramming in Diabetes 93. Hui X, Zhang M, Gu P, Li K, Gao Y, Wu D, Wang Y, Xu A. Adipocyte SIRT 1 controls systemic insulin sensitivity by modulating macrophages in adipose tissue . EMBO Rep (2017) 18:645–657. doi: 10.15252/embr.201643184 94. Gillum MP, Kotas ME, Erion DM, Kursawe R, Chatterjee P, Nead KT, Muise ES, Hsiao JJ, Frederick DW, Yonemitsu S, et al. SirT1 regulates adipose tissue inflammation. Diabetes (2011) 60:3235–3245. doi: 10.2337/db11-0616 95. Dai H, Sinclair DA, Ellis JL, Steegborn C. Sirtuin activators and inhibitors: Promises, achievements, and challenges. Pharmacol Ther (2018) 188:140–154. doi: 10.1016/j. pharmthera.2018.03.004 96. Yoshizaki T, Schenk S, Imamura T, Babendure JL, Sonoda N, Bae EJ, Oh DY, Lu M, Milne JC, Westphal C, et al. SIRT1 inhibits inflammatory pathways in macrophages and modulates insulin sensitivity. Am J Physiol Endocrinol Metab (2010) 298: doi: 10.1152/ajpendo.00417.2009 97. Leus NGJ, van der Wouden PE, van den Bosch T, Hooghiemstra WTR, Ourailidou ME, Kistemaker LEM, Bischoff R, Gosens R, Haisma HJ, Dekker FJ. HDAC 3-selective inhibitor RGFP966 demonstrates anti-inflammatory properties in RAW 264.7 macrophages and mouse precisioncut lung slices by attenuating NF-κB p65 transcriptional activity. Biochem Pharmacol (2016) 108:58–74. doi: 10.1016/j.bcp.2016.03.010 98. Leus NGJ, van den Bosch T, van der Wouden PE, Krist K, Ourailidou ME, Eleftheriadis N, Kistemaker LEM, Bos S, Gjaltema RAF, Mekonnen SA, et al. HDAC1-3 inhibitor MS-275 enhances IL10 expression in RAW264.7 macrophages and reduces cigarette smoke-induced airway inflammation in mice. Sci Rep (2017) 7:1–18. doi: 10.1038/srep45047 99. Oh BR, Suh D hyeon, Bae D, Ha N, Choi Y il, Yoo HJ, Park JK, Lee EY, Lee EB, Song YW. Therapeutic effect of a novel histone deacetylase 6 inhibitor, CKD-L, on collagen-induced arthritis in vivo and regulatory T cells in rheumatoid arthritis in vitro. Arthritis Res Ther (2017) 19: doi: 10.1186/s13075-017-1357-2 100. Eckschlager T, Plch J, Stiborova M, Hrabeta J. Histone deacetylase inhibitors as anticancer drugs. Int J Mol Sci (2017) 18: doi: 10.3390/ijms18071414 101. Meier BC, Wagner BK. Inhibition of HDAC3 as a strategy for developing novel diabetes therapeutics. Epigenomics (2014) 6:209–214. doi: 10.2217/epi.14.11 102. Galmozzi A, Mitro N, Ferrari A, Gers E, Gilardi F, Godio C, Cermenati G, Gualerzi A, Donetti E, Rotili D, et al. Inhibition of class i histone deacetylases unveils a mitochondrial signature and enhances oxidative metabolism in skeletal muscle and adipose tissue. Diabetes (2013) 62:732– 742. doi: 10.2337/db12-0548 103. Ferrari A, Fiorino E, Longo R, Barilla S, Mitro N, Cermenati G, Giudici M, Caruso D, Mai A, Guerrini U, et al. Attenuation of diet-induced obesity and induction of white fat browning with a chemical inhibitor of histone deacetylases. Int J Obes (2017) 41:289–298. doi: 10.1038/ ijo.2016.191 104. Bele S, Girada SB, Ray A, Gupta A, Oruganti S, Babu PP, Rayalla RSR, Kalivendi SV, Ibrahim A, Puri V, et al. Ms-275, a class 1 histone deacetylase inhibitor augments glucagon-like peptide-1 receptor agonism to improve glycemic control and reduce obesity in diet-induced obese mice. Elife (2020) 9:1–33. doi: 10.7554/ELIFE.52212 105. Nicola NA, Burgess AW, Staber FG, Johnson GR, Metcalf D, Battye FL. Differential expression of lectin receptors during hemopoietic differntiation: Enrichment for granulocyte‐macrophage progenitor cells. J Cell Physiol (1980) 103:217–237. doi: 10.1002/jcp.1041030207 106. Ahl PJ, Hopkins RA, Xiang WW, Au B, Kaliaperumal N, Fairhurst AM, Connolly JE. Met-Flow, a strategy for single-cell metabolic analysis highlights dynamic changes in immune subpopulations. Commun Biol (2020) 3:1–15. doi: 10.1038/s42003-020-1027-9
RkJQdWJsaXNoZXIy MTk4NDMw